GNTA: To Present At Rodman & Renshaw Investment Conference @ 10:20 ET [delayed] -
Genta Incorporated Announces Third Quarter 2008 Financial Results and Corporate Highlights -
Genta Incorporated to Host Conference Call to Discuss Third Quarter Highlights and Financial Results -
GNTA: Conference call regarding Annual Shareholders Meeting @ 11:00 ET Today [delayed] -
Genta to Stay Trading Below $1 -
Genta's Phase III melanoma study receives positive review from DMB -
GNTA: Independent Monitoring Board Recommends Completion of PH 3 AGENDA Trial -
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights -
Genta Announces Second Quarter 2008 Financial Results and Conference Call -
Genta Tempered by Trial Costs -
FDA accepts Genta's NDA amendment for leukemia drug -
GNTA: FDA Accepts NDA Amendment for Genasense(R) as "Complete Response" -
FDA lifts clinical hold on Genta's cancer drug -
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma -
GNTA: FDA Lifts Clinical Hold on Tesetaxel Oral Taxane -
FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane -